Breast Cancer Treatment Protocols: Systematic Review of the Last 35 Years
Keywords:Breast cancer, protocols, systematic review.
Breast cancer is the main leading type of cancer for women around the world and is responsible for 522,000 deaths per year worldwide. In order to reduce this number, clinicians and researchers are always looking for new strategies and protocols. However, the treatment for breast cancer is challenging and requires as much information as possible. To this end, we conducted a review of all protocols used for breast cancer treatment in the last 35 years with the objective to help clinicians to choose the best treatment possible available in their region. Many of the protocols are international references, and for that reason have been used in many countries like USA and Europe. The data, depicted in tables, may be helpful for clinicians worldwide and researchers to better understand the evolution of breast cancer protocols such as helping make daily routine decisions.
Miller DK, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271-289. https://doi.org/10.3322/caac.21349
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30. https://doi.org/10.3322/caac.21332
Scalia-Wilbur J, et al. Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. Semin Radiat Oncol 2016; 26(1): 3-8. https://doi.org/10.1016/j.semradonc.2015.09.004
Tang Y, et al. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30108-2.
Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368. https://doi.org/10.1634/theoncologist.2008-0230
Abramovitz M, et al. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30146-X.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
Bernier J, et al. Surgery and radiation therapy of triplenegative breast cancers: From biology to clinics. Breast 2016; 28: 148-55. https://doi.org/10.1016/j.breast.2016.05.014
Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002; 21: 3511-3526. https://doi.org/10.1002/sim.1304
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-271. https://doi.org/10.3322/caac.21235
Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 2009; 115: 2999-3008. https://doi.org/10.1002/cncr.24363
McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009; 16: 2682-2690. https://doi.org/10.1245/s10434-009-0635-x
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015; 150: 9-16. https://doi.org/10.1001/jamasurg.2014.2895
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792. https://doi.org/10.1056/NEJMoa050518
Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016; 34: 611-635. https://doi.org/10.1200/JCO.2015.64.3809
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 386-405. https://doi.org/10.1093/jnci/djr541